Hemophilia A (HA) is an X-linked bleeding disorder caused by a wide variety of mutations in the factor 8 (F8) gene, leading to absent or deficient factor VIII (FVIII). We analyzed the F8 gene of 267 unrelated Spanish patients with HA. After excluding patients with the common intron-1 and intron-22 inversions and large deletions, we detected 137 individuals with small mutations, 31 of which had not been reported previously. Eleven of these were nonsense, frameshift, and splicing mutations, whereas 20 were missense changes. We assessed the impact of the 20 substitutions based on currently available information about FV and FVIII structure and function relationship, including previously reported results of replacements at these and topologically equivalent positions. Although most changes are likely to cause gross structural perturbations and concomitant cofactor instability, p.Ala375Ser is predicted to affect cofactor activation. Finally, 3 further mutations (p.Pro64Arg, p.Gly494Val, and p.Asp2267Gly) appear to affect cofactor interactions with its carrier protein, von Willebrand factor, with the scavenger receptor low-density lipoprotein receptor–related protein (LRP), and/or with the substrate of the FVIIIapi•FIXa (Xase) complex, factor X. Characterization of these novel mutations is important for adequate genetic counseling in HA families, but also contributes to a better understanding of FVIII structure-function relationship.

Deleterious changes in the human F8 gene reduce activity and/or circulating plasma levels of factor VIII (FVIII) protein causing hemophilia A (HA). Patients with HA are classified according to their plasma procoagulant levels of FVIII: severe (< 0.01 IU/mL), moderate (0.01-0.05 IU/mL), or mild (0.05-0.4 IU/mL).1  The F8 gene is located at Xq28 and spans 186 kb genomic DNA, with 26 exons. Mature FVIII is composed of 2332 residues with an A1-a1-A2-a2-B-a3-A3-C1-C2 domain organization. The 3 A domains are homologous to the plasma ferroxidase, ceruloplasmin, while the 2 C-terminal domains belong to the widespread family of discoidin-like modules. The A and C domains of FVIII are also similar to those of coagulation factor V, and adopt similar quaternary structures in both activated cofactors.2,3  By contrast, the heavily glycosylated B domain is related neither to the corresponding FV region nor to any other reported protein. Domains A1/A2, A2/B, and B/A3 are connected by relatively long linkers rich in acidic residues, which are termed a1 to a3. None of these peptides has homologs in ceruloplasmin, while a2 and a3, but not a1, have functional counterparts in FV.

FVIII circulates in plasma bound to the carrier protein, von Willebrand factor (VWF), as multiple heterodimeric forms containing various lengths of the B-subunit covalently attached to the A1-a1-A2-a2 region (the heavy chain) and an a3-A3-C1-C2 light chain. Cofactor activation requires thrombin-mediated cleavage of peptide bonds Arg372-Ser373 (in the a1-A2 linker), Arg740-Ser741 (a2-B), and Arg1689-Ser1690 (a3-A3); exosite-mediated thrombin interactions with the acidic a1-a3 peptides appear to be essential for these proteolytic cleavages. The resulting A1-a1/A2-a2/A3-C1-C2 heterotrimer no longer interacts with VWF but binds to the serine protease, FIXa, on negatively charged phospholipid membranes provided by activated platelets. This calcium-dependent complex of FVIIIa, FIXa, and acidic phospholipids, also termed intrinsic Xase, activates FX via cleavage of a single peptide bond (Figure 1A; recently reviewed by Fay and Jenkins4  and Graw et al5 ). In addition to its role in cofactor activation, the acidic region a1 is involved in important interactions with the Xase substrate, FX.6,7 

Figure 1

Structure and function of Xase complex. (A) Schematic representation of Xase complex and mechanism of factor X activation. The major structural domains of cofactor VIIIa, its cognate protease FIXa, and substrate FX are labeled, and represented in the approximate positions they would occupy in the Xase complex. The long FX activation peptide is also indicated as a ribbon, pointing to the insertion of the Arg194(15)-Ile195(16) activation peptide bond in the active site of FIXa. (Numbers in parentheses refer to the standard chymotrypsinogen numbering system.) Gla indicates γ-carboxyglutamic–rich domain; EGF1/EGF2, epidermal growth factor–like domains 1 and 2; and SP, serine protease domain. (B) Three-dimensional model of human FVIIIa, highlighting the side chains of all novel missense mutations identified in the current investigation (light magenta spheres). The 5 FVIIIa domains are represented with their major secondary structure elements and color-coded as in panel A. For clarity, only selected residues are labeled, including the 4 exposed residues Arg64, Ala375, Gly494, and Asp2267 (boxed). The acidic a1 and a2 peptides are included only to indicate their locations on opposite poles of domain A2, as no appropriate templates are available for them. Selected side chains of hydrophobic residues in C1/C2 domains that would associate with the phospholipid membrane are in green. Some previously detected mutations of exposed residues are shown as yellow sticks; for clarity, only a few of these residues are labeled (see “Discussion” for details and references). Considering these previous analyses of FVIII mutants, residues important for cognate FIXa binding cluster to the right in the chosen orientation (eg, stretches Ser558-Gln565, Asp712/Lys713, and Glu1811-Lys1819), while those involved in FX recognition map to the left in this orientation (see, eg, the location of the acidic a1 peptide). This clear segregation of residues critical for FIXa/FX binding allows us to predict important roles for residues Pro64, Gly494, and Asp2267 in substrate binding and presentation to the FVIIIapi•FIXa (Xase) complex.

Figure 1

Structure and function of Xase complex. (A) Schematic representation of Xase complex and mechanism of factor X activation. The major structural domains of cofactor VIIIa, its cognate protease FIXa, and substrate FX are labeled, and represented in the approximate positions they would occupy in the Xase complex. The long FX activation peptide is also indicated as a ribbon, pointing to the insertion of the Arg194(15)-Ile195(16) activation peptide bond in the active site of FIXa. (Numbers in parentheses refer to the standard chymotrypsinogen numbering system.) Gla indicates γ-carboxyglutamic–rich domain; EGF1/EGF2, epidermal growth factor–like domains 1 and 2; and SP, serine protease domain. (B) Three-dimensional model of human FVIIIa, highlighting the side chains of all novel missense mutations identified in the current investigation (light magenta spheres). The 5 FVIIIa domains are represented with their major secondary structure elements and color-coded as in panel A. For clarity, only selected residues are labeled, including the 4 exposed residues Arg64, Ala375, Gly494, and Asp2267 (boxed). The acidic a1 and a2 peptides are included only to indicate their locations on opposite poles of domain A2, as no appropriate templates are available for them. Selected side chains of hydrophobic residues in C1/C2 domains that would associate with the phospholipid membrane are in green. Some previously detected mutations of exposed residues are shown as yellow sticks; for clarity, only a few of these residues are labeled (see “Discussion” for details and references). Considering these previous analyses of FVIII mutants, residues important for cognate FIXa binding cluster to the right in the chosen orientation (eg, stretches Ser558-Gln565, Asp712/Lys713, and Glu1811-Lys1819), while those involved in FX recognition map to the left in this orientation (see, eg, the location of the acidic a1 peptide). This clear segregation of residues critical for FIXa/FX binding allows us to predict important roles for residues Pro64, Gly494, and Asp2267 in substrate binding and presentation to the FVIIIapi•FIXa (Xase) complex.

Close modal

The crystal structure of the FVIII C2 domain8  and those of human ceruloplasmin9  and bovine inactivated FVa (FVai; Adams et al2 ) have provided valuable templates for developing FVIIIa models of increased accuracy (see, eg, Pemberton et al,10  Liu et al,11  Stoilova-McPhie et al,12  and Autin et al13 ). The recently reported crystal structure of human FVIIIa at low resolution3  confirmed that the side-by-side arrangement of C1 and C2 domains previously observed in bovine FVai2  and incorporated in a recent modeling study13  is the most likely conformation for both cofactors, at least in their uncomplexed states. On the other hand, identification of novel mutations leading to HA and their thorough analysis has helped to define areas involved in important interdomain contacts, membrane binding, as well as in interactions with cognate FIXa and substrate, FX.4,5  Therefore, characterization of F8 mutations is important for a better understanding of the structure-function relationship of the FVIII molecule. As of January 2007, more than 580 missense mutations have been deposited with the HAMSTeRS database,14  and recent investigations have added a large number of mutations in different populations (see, eg, David et al,15  Guillet et al,16  Repesse et al,17  and Rossetti et al18 ).

Here, we characterized 31 novel small mutations in the F8 gene, including 11 nonsense, frameshift, and splicing mutations as well as 20 missense mutations. We also provide a thorough evaluation of the probable structural and/or functional defects caused by these residue replacements.

Patients

We analyzed the F8 gene in 267 unrelated patients with clinical and laboratory confirmation of HA after obtaining their informed consent in accordance with the Declaration of Helsinki. Approval was obtained from the Ethical Committee from the Hospital of Sant Pau institutional review board for these studies. One hundred ninety-three patients were classified as severe HA and the remaining 72 were moderate to mild cases. Moreover, the patients were defined as familial (positive) or isolated (sporadic) according to their available pedigree information.

DNA isolation and sequencing

DNA was isolated from peripheral blood samples using the salting-out method. After excluding hemophiliacs with intron 1 and intron 22 inversions and with large deletions, all 26 exons and exon-intron boundaries of the F8 gene from the remaining patients were amplified using primers and polymerase chain reaction (PCR) conditions essentially as in David et al19  and as deposited in the HAMSTeRS database.14  Promoter analysis was performed as previously described.20  The amplified fragments were purified with QIAquick columns (Qiagen, Isaza, Barcelona, Spain), and analyzed by direct forward and reverse sequencing using a DNA sequencing kit (PerkinElmer-Applied Biosystems, Madrid, Spain) on an ABI PRISM 3100 Avant DNA automatic sequencer (Applied Biosystems, Madrid, Spain).

Nomenclature

Nucleotide numbering was based on the cDNA sequence (GenBank no. NM_000132.2.21 ), with nucleotide +1 corresponding to the adenine of the ATG translation initiation codon. The amino acid numbering system was based on the mature protein, while residues from the 19-residues–long signal peptide were numbered in reverse. Thus, the initial methionine was numbered as −19 and the first alanine of the mature protein was numbered as +1. The nomenclature used to describe mutations is that of den Dunnen and Antonarakis.22 

For residues surrounding activation cleavage sites, we used the standard Schechter and Berger nomenclature23 : substrate residues are denoted Pm, …, P1, P1′, … Pn′, with the scissile peptide bond located between P1 and P1′.

Analysis of missense mutations

We ascertained that a given missense mutation is causally related to the patient's HA phenotype in accordance with the following criteria: (1) the mutation cosegregated in other affected individuals or carriers from the same family; (2) it was not detected in a panel of 100 X-chromosomes from the general Spanish population; (3) no other nucleotide change was found in the F8 coding region or in exon-intron boundaries; (4) the mutated residue was conserved or conservatively replaced in FVIII from different species, and in most cases in FV and/or ceruloplasmin; and (5) finally, most mutated residues are buried in the protein core, and their replacement would either disrupt networks of buried hydrogen bonds, create destabilizing internal cavities, and/or lead to clashes with neighboring residues. The predicted impact of missense mutations in FVIIIa as well as in equivalent positions of FVai and ceruloplasmin was assessed with PolyPhen (http://genetics.bwh.harvard.edu/pph/, Harvard University) and CUPSAT (http://cupsat.tu-bs.de/, Cologne University).24 

Homology modeling

We separately submitted alignments of the A1-a1-A2-a2-A3 and C1 domains of FV, FVIII, and ceruloplasmin from different species to the Swiss-Model server.25,26  For the A1-a1-A2-a2-A3 substructure, we used as a template the crystal structure of ceruloplasmin (PDB code 1KCW),9,27  while the FVIII C1 domain was modeled based on the homologous C2 domain (Pratt et al8 ; PDB code 1D7P). (Proteolytic inactivation of FVa leads to the loss of domain A2 and a concomitant destabilization of nearby domain A1, and therefore the structure of ceruloplasmin represents a better template for modeling the A1-A2-A3 trimer.) The cysteine residue covalently linked to Cys2296 was removed from the 1D7P entry, and the partial models for FVIII A1/A2/A3, C1, and C2 domains were superimposed on the structure of inactivated bovine FVa (PDB 1SDD). Coordinates for bound calcium and copper ions were taken from the latter structure. After manual readjustment of side chains at the interdomain interfaces, especially those involved in cation-binding sites, the resulting trimer was finally minimized with CNS (http://cns.csb.yale.edu/v1.1/, Yale University). FX models were constructed using the partial crystal structures for EGF1-EGF2 catalytic domain (1XKA)28  and Gla domain (1IOD),29  as well as the solution structure of the Gla-EGF1 tandem (1WHF)30 ; the structure of bovine chymotrypsinogen A was selected to generate FX zymogen conformation (2CGA).31  FIXa was modeled essentially following the structure of the porcine cofactor32 ; the Gla domain was derived from 1J3433  and 1NL0.34  Similar strategies have been followed by other authors to generate FIXa/FX models.13,29,35  Model quality was assessed with MOLEMAN2 (http://xray.bmc.uu.se/cgi-bin/gerard/rama_server.pl, Uppsala Software Factory, Uppsala, Sweden); for FVIIIa, that is, 89% of all residues were found in core regions of the Ramachandran plot. Docking was performed with ZDOCK (http://zdock.bu.edu/, Boston University) and structure figures were generated with PyMOL (http://www.pymol.org, DeLano Scientific, Palo Alto, CA).

After submission of this work, a 3.7-Å crystal structure of human FVIIIa was presented.3  Although the coordinates for the latter are not yet available, the reported similarity to the previous FVai structure validates all relevant features of the current “compact” model. In particular, the side-by-side arrangement of the C1 and C2 domains is supported by a large hydrophobic/aromatic interface between domains A3 and C1, while C2 lacks important interactions with the remaining domains (Figure 1B). These features are in line with an overall conservation of residues that form the A3-C1 interface in the 2 cofactors.2,3  Moreover, experimental evidence suggests absence of important contacts between the A2 domain and the cofactor light chain, while interactions with A1 account for 90% of the interchain binding energy.36  Altogether, current evidence would seem to disfavor a FVIIIa model where domain C1 is located on top of C2 (and thus removed from the phospholipid membrane),12  and which has been commonly used to rationalize the effect of point mutations on FVIIIa structure.

By contrast, the compact arrangement of globular domains is likely to reproduce the conformation of membrane-bound cofactors Va and VIIIa. We note that topologically equivalent, exposed hydrophobic residues from both discoidin-like domains of FVa37-39  and FVIIIa11,40,41  appear to be involved in membrane binding (for a review on structures and interactions mediated by these discoidin-like domains, see Fuentes-Prior et al42 ). In particular, the exposed Tyr1956/Leu1957 pair in the first spike of the human FV C1 domain corresponds to human FVIII residues Lys2092 and Phe2093 (Figure 2B boxed), while arginine residues at positions 2023 and 2027 are conserved as Arg2159 and Arg2163 in human FVIII. As demonstrated for the FVa residues,38  the side chains of these topologically equivalent, solvent-exposed FVIIIa residues (eg, Lys2092, Arg2159, Arg2163) could interact with negatively charged phosphatidylserine headgroups,11  while Phe2093 could be inserted into the apolar membrane core, stabilizing the side-by-side arrangement on procoagulant phospholipid membranes (see Figure 1B, where side chains of some of these residues are shown in green).

Figure 2

Multiple partial alignments of factor V, factor VIII, and ceruloplasmin from different species around FVIII positions where novel mutations were found in the current work. For simplicity, only mutations within domain A1 and the A1-A2 linker (part A) and domains C1/C2 (part B) are represented; a complete alignment is available from the authors upon request. Strictly conserved residues are white with black shading, and conservative changes are shaded gray. Numberings refer to the mature human proteins. The activation cleavage site is indicated with an arrow in panel A, and loops important for membrane association are boxed in panel B. The secondary structure elements given below FV and ceruloplasmin sequences correspond to the crystal structures of bovine inactivated FVa (PDB 1SDD, Adams et al2 ), FVIII C2 domain (1D7P, Pratt et al8 ), and human ceruloplasmin (1KCW, Zaitseva et al9 ), as deposited in the corresponding PDB entries. Residues that are disordered in the crystal structure of ceruloplasmin are underlined.

Figure 2

Multiple partial alignments of factor V, factor VIII, and ceruloplasmin from different species around FVIII positions where novel mutations were found in the current work. For simplicity, only mutations within domain A1 and the A1-A2 linker (part A) and domains C1/C2 (part B) are represented; a complete alignment is available from the authors upon request. Strictly conserved residues are white with black shading, and conservative changes are shaded gray. Numberings refer to the mature human proteins. The activation cleavage site is indicated with an arrow in panel A, and loops important for membrane association are boxed in panel B. The secondary structure elements given below FV and ceruloplasmin sequences correspond to the crystal structures of bovine inactivated FVa (PDB 1SDD, Adams et al2 ), FVIII C2 domain (1D7P, Pratt et al8 ), and human ceruloplasmin (1KCW, Zaitseva et al9 ), as deposited in the corresponding PDB entries. Residues that are disordered in the crystal structure of ceruloplasmin are underlined.

Close modal

Finally, we would like to stress that models for FVIIIa and FVIIIapi•FIXa complexes based on the bovine FVai structure have been developed by Autin et al following a similar strategy.13  These models, however, have not been used to date to predict the impact of missense mutations in the F8 gene.

We identified 137 small mutations in the 267 Spanish HA patients studied in the current work (the remaining 130 patients had intron 1 and 22 inversions and large deletions). Ninety-one of these mutations were missense, 10 were of the nonsense type, 29 were small deletions or insertions, and 7 were splice site mutations (data not shown; available upon request). In particular, we detected 31 novel changes (none deposited to date in the HAMSTeRS database nor reported in recently published articles), including 2 nonsense, 7 frameshift, and 2 splicing mutations (Table 1). Three of these hemophiliacs have developed inhibitors to FVIII.

Table 1

Novel nonsense, small deletions, small insertions, tandem duplications, and splice site mutations detected in Spanish HA patients

Exon/intron*MutationCodonDomainClinical severityInhibitorsFamily history
c.1251insC p.Leu398fsX7 A2 Severe No Sporadic 
11 c.1682delA p.Asp542fsX2 A2 Severe No Sporadic 
14 c.2766delC p.Ser903fsX2 Moderate No Positive 
14 c.3093delAAGA p.Lys1012fsX9 Severe Yes Positive 
14 c.3557delT p.Phe1167_8fsX31 Severe No Sporadic 
14 c.4155_4195dup p.Thr1366ThrfsX4 Severe Yes Sporadic 
16 c.5508_5521del p.Trp1817fsX32 A3 Severe No Sporadic 
17 c.5805T>A p.Tyr1916Stop A3 Severe Sporadic 
20 c.6135G>T p.Gly2026Stop C1 Severe No Sporadic 
13* IVS13 a-2g — — Severe Yes Sporadic 
15* IVS15 g-1c — — Severe No Sporadic 
Exon/intron*MutationCodonDomainClinical severityInhibitorsFamily history
c.1251insC p.Leu398fsX7 A2 Severe No Sporadic 
11 c.1682delA p.Asp542fsX2 A2 Severe No Sporadic 
14 c.2766delC p.Ser903fsX2 Moderate No Positive 
14 c.3093delAAGA p.Lys1012fsX9 Severe Yes Positive 
14 c.3557delT p.Phe1167_8fsX31 Severe No Sporadic 
14 c.4155_4195dup p.Thr1366ThrfsX4 Severe Yes Sporadic 
16 c.5508_5521del p.Trp1817fsX32 A3 Severe No Sporadic 
17 c.5805T>A p.Tyr1916Stop A3 Severe Sporadic 
20 c.6135G>T p.Gly2026Stop C1 Severe No Sporadic 
13* IVS13 a-2g — — Severe Yes Sporadic 
15* IVS15 g-1c — — Severe No Sporadic 

? indicates not available; and —, not applicable.

The remaining 20 mutations were of the missense type for which the criteria described in “Analysis of missense mutations” apply; a detailed description of these mutations is shown in Table 2. According to available information, none of the patients from this group developed inhibitors. All globular domains of the activated cofactor were affected by these novel missense mutations (see Figure 1B, where mutated residues are shown with all their side chain atoms in the FVIIIa model). In line with the greater functional relevance of domains A1 and A2 for FIXa/FX binding, 60% (12/20) of the novel mutations affect residues within one of these domains (6 changes in each domain). Two further mutations were identified in domain A3, 4 in C1, and 2 in the second discoidin-like domain. To illustrate the location of affected positions, partial multiple alignments of FV, FVIII, and ceruloplasmin sequences from different species around all mutated residues in domain A1 are presented in Figure 2A. Similarly, partial alignments around mutations found in C1 and C2 domains from both coagulation factors are given in Figure 2B. These changes are representative of the 20 novel missense mutations identified in the current work, and range from strictly conserved, buried residues that belong to major secondary-structure elements (eg, p.Asp167Asn) to solvent-exposed loop residues that are unique to FVIII (eg, p.Ala375Ser).

Table 2

Novel missense mutations detected in Spanish HA patients

ExonDomainMutation
Clinical severityFamily historyConservation in FVIII/FV/CpPolyPhen predictionPredicted structural and/or functional implication
NucleotideProtein
2* A1 c.248C>G p.Pro64Arg Mild Positive Yes/yes/no Probably damaging Impaired FX binding 
A1 c.556G>A p.Asp167Asn Severe Positive Yes/yes/yes Benign Eliminates H-bond network/Disrupts domain structure 
A1 c.584T>C p.Leu176Pro Severe Sporadic Yes/yes/yes Possibly damaging Creates cavity in protein core/disrupts secondary structure 
A1 c.762A>G p.Asn235Ser Severe Sporadic Yes/yes/yes Benign Eliminates H-bond network/disrupts domain structure 
A1 c.782T>C p.Leu242Pro Moderate Sporadic Yes/cons/yes Possibly damaging Creates cavity in protein core 
A1 c.839G>A p.Gly261Asp Mild Sporadic Yes/no/yes Possibly damaging Introduces acidic side chain in unfavorable environment 
8* A2 c.1180G>T p.Ala375Ser Mild Positive Yes/no/no Benign Change at P3′ position/delayed factor VIII activation 
A2 c.1421G>T p.Gly455Val Mild NA Yes/no/no Probably damaging Steric clashes with mostly aliphatic residues 
10 A2 c.1487C>G p.Pro477Arg Severe Sporadic Yes/yes/yes Probably damaging Major disruption of protein core 
11* A2 c.1538G>T p.Gly494Val Moderate Positive Yes/no/no Probably damaging Impaired FX binding/enhanced binding to LRP 
11 A2 c.1706C>G p.Pro550Arg Severe Sporadic Yes/no/yes Probably damaging Major disruption of protein core 
13 A2 c.1910A>T p.Asn618Ile Moderate Sporadic Yes/yes/yes Probably damaging Eliminates stabilizing H-bond interactions 
14 A3 c.5159C>T p.Ala1701Val Mild Positive Yes/yes/yes Benign Steric clashes with mostly aromatic or polar residues 
15 A3 c.5286T>A p.Phe1743Leu Moderate Sporadic Yes/yes/yes Possibly damaging Creates small cavity in domain core/Disrupts loop conformation 
22 C1 C.6301C>G p.His2082Asp Mild Positive Yes/no/— Probably damaging Disrupts interactions between domains A3 and C1 
22 C1 C.6317A>C p.Gln2087Pro Severe Positive Yes/yes/— Possibly damaging Eliminates H-bond network/disrupts domain structure 
22 C1 C.6427A>G p.Met2124Val Mild Sporadic Yes/yes/— Possibly damaging Creates small cavity in protein core 
23 C1 C.6515C>T p.Pro2153Leu Severe Positive Yes/yes/— Probably damaging Disrupts protein core 
25* C2 C.6857A>G p.Asp2267Gly Mild Sporadic Yes/no/— Possibly damaging Impaired FX- and/or VWF-binding 
26 C2 C.7006A>T p.Ile2317Phe Moderate Positive Yes/yes/— Benign Disrupts protein core 
ExonDomainMutation
Clinical severityFamily historyConservation in FVIII/FV/CpPolyPhen predictionPredicted structural and/or functional implication
NucleotideProtein
2* A1 c.248C>G p.Pro64Arg Mild Positive Yes/yes/no Probably damaging Impaired FX binding 
A1 c.556G>A p.Asp167Asn Severe Positive Yes/yes/yes Benign Eliminates H-bond network/Disrupts domain structure 
A1 c.584T>C p.Leu176Pro Severe Sporadic Yes/yes/yes Possibly damaging Creates cavity in protein core/disrupts secondary structure 
A1 c.762A>G p.Asn235Ser Severe Sporadic Yes/yes/yes Benign Eliminates H-bond network/disrupts domain structure 
A1 c.782T>C p.Leu242Pro Moderate Sporadic Yes/cons/yes Possibly damaging Creates cavity in protein core 
A1 c.839G>A p.Gly261Asp Mild Sporadic Yes/no/yes Possibly damaging Introduces acidic side chain in unfavorable environment 
8* A2 c.1180G>T p.Ala375Ser Mild Positive Yes/no/no Benign Change at P3′ position/delayed factor VIII activation 
A2 c.1421G>T p.Gly455Val Mild NA Yes/no/no Probably damaging Steric clashes with mostly aliphatic residues 
10 A2 c.1487C>G p.Pro477Arg Severe Sporadic Yes/yes/yes Probably damaging Major disruption of protein core 
11* A2 c.1538G>T p.Gly494Val Moderate Positive Yes/no/no Probably damaging Impaired FX binding/enhanced binding to LRP 
11 A2 c.1706C>G p.Pro550Arg Severe Sporadic Yes/no/yes Probably damaging Major disruption of protein core 
13 A2 c.1910A>T p.Asn618Ile Moderate Sporadic Yes/yes/yes Probably damaging Eliminates stabilizing H-bond interactions 
14 A3 c.5159C>T p.Ala1701Val Mild Positive Yes/yes/yes Benign Steric clashes with mostly aromatic or polar residues 
15 A3 c.5286T>A p.Phe1743Leu Moderate Sporadic Yes/yes/yes Possibly damaging Creates small cavity in domain core/Disrupts loop conformation 
22 C1 C.6301C>G p.His2082Asp Mild Positive Yes/no/— Probably damaging Disrupts interactions between domains A3 and C1 
22 C1 C.6317A>C p.Gln2087Pro Severe Positive Yes/yes/— Possibly damaging Eliminates H-bond network/disrupts domain structure 
22 C1 C.6427A>G p.Met2124Val Mild Sporadic Yes/yes/— Possibly damaging Creates small cavity in protein core 
23 C1 C.6515C>T p.Pro2153Leu Severe Positive Yes/yes/— Probably damaging Disrupts protein core 
25* C2 C.6857A>G p.Asp2267Gly Mild Sporadic Yes/no/— Possibly damaging Impaired FX- and/or VWF-binding 
26 C2 C.7006A>T p.Ile2317Phe Moderate Positive Yes/yes/— Benign Disrupts protein core 

Cp indicates ceruloplasmin; H-bond, hydrogen bond; NA, not available; and —, not applicable.

*

Type II mutations (further explanation in “Type II mutations”).

Further, and based on structural analysis (Figures 3,4; Tables S1,S2, available on the Blood website; see the Supplemental Materials link at the top of the online article) and on consideration of previously reported mutants (Table 3), we interpreted missense mutations as those likely to result in type I or quantitative FVIII deficiency and as those likely to affect cofactor function—type II or qualitative cofactor deficiency. The majority of identified mutations within the first group replace well-conserved, fully or partially buried residues, which is similar to data recently reported by other authors.14-17  Because these residues engage in multiple, mostly intradomain contacts, the ultimate result of these mutations would be an incorrectly folded and unstable cofactor molecule that is either poorly secreted and/or rapidly removed from circulation. There are, however, differences in the potential impact of a particular mutation as a function of its location (eg, whether the residue is part of a regular secondary structure element or found within a loop) and the nature of the replacing residue (“Discussion”).

Figure 3

Close-up of novel, putative type I missense mutations identified in the current study. Atoms are color-coded (green indicates carbon; blue, nitrogen; red, oxygen; and yellow, sulfur), and the mutated residues are labeled yellow. With exception of Gly261 (E) and His2082 (K), only residues within 4 Å of the mutation are shown. Hydrogen bonds are indicated with dotted lines. Notice that most affected residues are fully buried in the protein core and engage in multiple interactions with surrounding residues. (Further explanation for each mutation is in “Type I mutations.”)

Figure 3

Close-up of novel, putative type I missense mutations identified in the current study. Atoms are color-coded (green indicates carbon; blue, nitrogen; red, oxygen; and yellow, sulfur), and the mutated residues are labeled yellow. With exception of Gly261 (E) and His2082 (K), only residues within 4 Å of the mutation are shown. Hydrogen bonds are indicated with dotted lines. Notice that most affected residues are fully buried in the protein core and engage in multiple interactions with surrounding residues. (Further explanation for each mutation is in “Type I mutations.”)

Close modal
Figure 4

Comparison of loop structures around FVIII C2 residue, Asp2267. The crystal structures of recombinant C2 domains from FV (Macedo-Ribeiro et al72 ) and FVIII (Pratt et al8 ) were superimposed, and residues around the mutated Asp2267 (FVIII) and the topologically equivalent Gln2132 (FV) are shown. The main chains of factors V and VIII are represented as orange and green ribbons, respectively. Only side chains of Gln2132/Asp2267 and surrounding residues are shown with all their nonhydrogen atoms; the side chains of FV are in orange and those of FVIII are color-coded as in Figure 3. Hydrogen bonds accepted from the Asp2267 carboxylate are indicated with dotted lines. Notice the complete equivalence of main-chain traces in the 2 cofactors, indicating that Asp2267 is dispensable for the observed loop conformation. Notice also that a large number of solvent-exposed side chains differ between the 2 cofactors, pointing to their involvement in specific protein-protein interactions. Inspection of the FVa/FVIIIa models suggests that these residues interact with substrates of the FVapi•FXa and FVIIIapi•FIXa complexes, prothrombin and FX, respectively.

Figure 4

Comparison of loop structures around FVIII C2 residue, Asp2267. The crystal structures of recombinant C2 domains from FV (Macedo-Ribeiro et al72 ) and FVIII (Pratt et al8 ) were superimposed, and residues around the mutated Asp2267 (FVIII) and the topologically equivalent Gln2132 (FV) are shown. The main chains of factors V and VIII are represented as orange and green ribbons, respectively. Only side chains of Gln2132/Asp2267 and surrounding residues are shown with all their nonhydrogen atoms; the side chains of FV are in orange and those of FVIII are color-coded as in Figure 3. Hydrogen bonds accepted from the Asp2267 carboxylate are indicated with dotted lines. Notice the complete equivalence of main-chain traces in the 2 cofactors, indicating that Asp2267 is dispensable for the observed loop conformation. Notice also that a large number of solvent-exposed side chains differ between the 2 cofactors, pointing to their involvement in specific protein-protein interactions. Inspection of the FVa/FVIIIa models suggests that these residues interact with substrates of the FVapi•FXa and FVIIIapi•FIXa complexes, prothrombin and FX, respectively.

Close modal
Table 3

Comparison of novel missense mutations in Spanish HA patients with previously reported replacements at the same or topologically equivalent positions

Mutation/equivalent mutationsFVIII:C, %FVIII:Ag, %Clinical severityInhibitor?Reference
p.Asp167Asn      
    p.Asp167Tyr <1 1.6 Moderate No Liu et al68  
    p.Asp167Glu 9-15 Mild Boekhorst et al19  
    p.Asp167Gly Mild Cutler et al74  
    p.Asp542Tyr <1 <1 Severe No Akkarapatumwong et al75  
    p.Asp542Gly <1 Severe No Higuchi et al76 ; McGinniss et al77  
    p.Asp542His <1 Severe No Waseem et al55 ; Bogdanova et al78  
    p.Asp542Ala <1 Severe No Tagariello et al, unpublished§ 
    p.Asp1846Tyr <1 Severe No Becker et al79  
    p.Asp1846Asn <1 Severe No Becker et al79  
    p.Asp1846Gly <1 Severe No Casana et al80  
    p.Asp1846Glu <1 Severe No Ljung et al, unpublished§ 
p.Asn235Ser      
    p.Asn235Ile <1 Severe Bicocchi et al81  
    p.Asn235Asp <1 Severe No Ljung et al, unpublished§ 
p.Asn618Ile      
    p.Asn618Asp Severe Leuer et al53  
    p.Asn618Asp Moderate Arruda et al82  
    p.Asn618Ser 31 22 Mild Roelse et al45  
    p.Asn618Ser 30 Mild Yes Vlot et al46  
    p.Asn618Ser Mild Boekhorst19  
    p.Ans618Ser <1 Severe No Ljung et al, unpublished§ 
    p.Asn1922Asp <1 Severe Yes Traystman et al47  
    p.Asn1922Asp Moderate Higuchi et al76  
    p.Asn1922Ser Severe Higuchi et al76  
    p.Asn1922Ser Moderate Diamond et al83  
p.Leu242Pro      
    p.Leu625Val 8-12 Mild No Freson et al49 ; Gallardo et al, unpublished§ 
    p.Leu625Ser <1 Severe No Guillet et al15  
    p.Leu1929Pro Cutler et al74  
p.Gly261Asp      
    p.Gly643Ala* <1 Severe No Gallardo et al, unpublished§ 
    p.Gly1948Asp 49 Mild/moderate No David et al18  
    p.Gly1948Arg 12 Mild No Ljung et al, unpublished§ 
p.Gly455Val      
    p.Ala78Pro <1 Severe Yes Sukarova-Stefanovska et al84  
    p.Gly455Glu Severe Yes Waseem et al55 ; Vinciguerra et al85  
    p.Gly455Arg <1 Severe No Freson et al49  
p.Gly494Val: p-Gly494Ser 23 Moderate Yes Liu et al68  
p.Pro550Arg      
    p.Ala175Thr 30 Mild No Guillet et al15  
    p.Pro1854Arg <1 Severe No Bogdanova et al78 ; Becker et al79  
    p.Pro1854Leu Mild Lillicrap et al, unpublished§ 
p.Ala1701Val: p.Ala1701Asp <1 Severe No David et al14  
p.Phe1743Leu      
    p.Phe436Cys Moderate No Cutler et al74  
    p.Phe436Cys Mild/moderate Bogdanova86  
    p.Phe1743Leu Mild Ahmed et al56  
p.Gln2087Pro      
    p.Gln2246Arg Moderate No Schwaab et al48  
    p.Glu2248Arg Mild/moderate Boekhorst et al19  
    p.Gln2246Lys 10 Mild No David et al14  
p.Pro2153Leu      
    p.Pro2153Gln Moderate No Schwaab et al48  
    p.Pro2153Glu <5 Mild/moderate Jacquemin et al51  
    p.Pro2153Arg <1 <1 Severe No Ivaskevicius et al52 ; Leuer et al53  
    p.Pro2310Leu <1 Severe No Bogdanova et al78  
p.Ile2317Phe: p.Ser2160Arg Moderate Ahmed et al56  
Mutation/equivalent mutationsFVIII:C, %FVIII:Ag, %Clinical severityInhibitor?Reference
p.Asp167Asn      
    p.Asp167Tyr <1 1.6 Moderate No Liu et al68  
    p.Asp167Glu 9-15 Mild Boekhorst et al19  
    p.Asp167Gly Mild Cutler et al74  
    p.Asp542Tyr <1 <1 Severe No Akkarapatumwong et al75  
    p.Asp542Gly <1 Severe No Higuchi et al76 ; McGinniss et al77  
    p.Asp542His <1 Severe No Waseem et al55 ; Bogdanova et al78  
    p.Asp542Ala <1 Severe No Tagariello et al, unpublished§ 
    p.Asp1846Tyr <1 Severe No Becker et al79  
    p.Asp1846Asn <1 Severe No Becker et al79  
    p.Asp1846Gly <1 Severe No Casana et al80  
    p.Asp1846Glu <1 Severe No Ljung et al, unpublished§ 
p.Asn235Ser      
    p.Asn235Ile <1 Severe Bicocchi et al81  
    p.Asn235Asp <1 Severe No Ljung et al, unpublished§ 
p.Asn618Ile      
    p.Asn618Asp Severe Leuer et al53  
    p.Asn618Asp Moderate Arruda et al82  
    p.Asn618Ser 31 22 Mild Roelse et al45  
    p.Asn618Ser 30 Mild Yes Vlot et al46  
    p.Asn618Ser Mild Boekhorst19  
    p.Ans618Ser <1 Severe No Ljung et al, unpublished§ 
    p.Asn1922Asp <1 Severe Yes Traystman et al47  
    p.Asn1922Asp Moderate Higuchi et al76  
    p.Asn1922Ser Severe Higuchi et al76  
    p.Asn1922Ser Moderate Diamond et al83  
p.Leu242Pro      
    p.Leu625Val 8-12 Mild No Freson et al49 ; Gallardo et al, unpublished§ 
    p.Leu625Ser <1 Severe No Guillet et al15  
    p.Leu1929Pro Cutler et al74  
p.Gly261Asp      
    p.Gly643Ala* <1 Severe No Gallardo et al, unpublished§ 
    p.Gly1948Asp 49 Mild/moderate No David et al18  
    p.Gly1948Arg 12 Mild No Ljung et al, unpublished§ 
p.Gly455Val      
    p.Ala78Pro <1 Severe Yes Sukarova-Stefanovska et al84  
    p.Gly455Glu Severe Yes Waseem et al55 ; Vinciguerra et al85  
    p.Gly455Arg <1 Severe No Freson et al49  
p.Gly494Val: p-Gly494Ser 23 Moderate Yes Liu et al68  
p.Pro550Arg      
    p.Ala175Thr 30 Mild No Guillet et al15  
    p.Pro1854Arg <1 Severe No Bogdanova et al78 ; Becker et al79  
    p.Pro1854Leu Mild Lillicrap et al, unpublished§ 
p.Ala1701Val: p.Ala1701Asp <1 Severe No David et al14  
p.Phe1743Leu      
    p.Phe436Cys Moderate No Cutler et al74  
    p.Phe436Cys Mild/moderate Bogdanova86  
    p.Phe1743Leu Mild Ahmed et al56  
p.Gln2087Pro      
    p.Gln2246Arg Moderate No Schwaab et al48  
    p.Glu2248Arg Mild/moderate Boekhorst et al19  
    p.Gln2246Lys 10 Mild No David et al14  
p.Pro2153Leu      
    p.Pro2153Gln Moderate No Schwaab et al48  
    p.Pro2153Glu <5 Mild/moderate Jacquemin et al51  
    p.Pro2153Arg <1 <1 Severe No Ivaskevicius et al52 ; Leuer et al53  
    p.Pro2310Leu <1 Severe No Bogdanova et al78  
p.Ile2317Phe: p.Ser2160Arg Moderate Ahmed et al56  

? indicates not available.

*

Mutation at the topologically equivalent position in human ceruloplasmin A2 domain, p.Gly631Arg, leads to impaired copper incorporation.45 

Reported as ″severe″ in the HAMSTeRS database.

Reported as ″moderate″ in the HAMSTeRS database. Altogether, absence of a fold-stabilizing side chain and cavity formation at this position appear to have less deleterious effects on the domain structure than clashes between side chains other than Asp and neighboring residues, in particular Trp208 (Figure 3A; Table S1).

§

Unpublished work included in this table has been deposited with the HAMSTeRS database.

Within the second group, 4 of the identified mutations affect residues that are exposed on the cofactor surface, which therefore do not engage in important intradomain or interdomain interactions (see Figure 1B, where labels for these residues are boxed). Further, these mutations map to regions that are only poorly conserved in FV/FVIII and ceruloplasmin (Figure 2), also suggesting a functional role. These considerations together with functional evidence presented for some related replacements allow us to hypothesize that these 4 mutants would lead to properly folded but functionally defective cofactor molecules.

We have detected 31 novel mutations in the F8 gene in Spanish HA patients, 9 of which were nonsense and small insertions and deletions. The deleterious mechanisms of these mutations are in general obvious given that they create premature termination codons leading to truncated F8 mRNA and FVIII protein.43  A particularly interesting case is mutation c.4155_4195dup, which introduces a 41-bp tandem duplication starting at nucleotide 4056 in exon 14. This would in turn predict a stop codon 4 triplets after the beginning of the duplication (ie, following residue Thr1366). The truncated mutant protein would lack domains C1 and C2 along with the C-terminal part of the B domain and therefore, critical elements required for VWF association and membrane binding. As expected, all but one of these novel mutations were associated with a severe phenotype. However, one patient with mutation c.2766delC predicting a stop codon after residue Ser903 showed moderate HA. Transcription errors or ribosomal frameshifting may result in the production of full-length FVIII in this case, as previously reported for other mutations (Bogdanova et al44  and references therein). The 2 novel splicing mutations were detected in patients with severe bleeding and are located at IVS13a-2g and IVS15g-1c affecting the specific consensus acceptor site. No RNA sample was available from these patients to confirm the effect of their mutations on splicing.

The predicted structural implications of the type I and type II novel missense changes are separately discussed below with emphasis on those positions where mutations of the same or topologically equivalent residues have previously been identified (Figure 3; Table 3; Table S1). Although the structural impact of these mutations was inferred from inspection of an FVIIIa homology model, quality and relatedness of substructures used as templates (crystal structures of human ceruloplasmin, human FVIII C2 domain, and bovine FVai) strongly support our analysis. In particular, most mutated residues are well conserved in FV and/or ceruloplasmin, and the effect of equivalent substitutions in the template structures can be directly assessed (Table S2).

Type I mutations

Missense mutations that affect polar, albeit fully buried side chains.

The apparently conservative replacement of the strictly conserved Asp167 (Figure 2A) by an asparagine would disrupt a complex network of stabilizing hydrogen bonds centered on Asp167 carboxylate (Figure 3A). All these H-bonds could not be simultaneously donated by the carboxamide group of an asparagine side chain, thus compromising domain A1 stability. Several different mutations have been previously identified at this and at topologically equivalent positions (Table 3). All well-characterized mutations were associated with severe phenotypes, as in p.Asp167Asn, with exception of the conservative replacement Asp→Glu.20 

Residues Asn235 and Asn618, which occupy topologically equivalent positions in domains A1 and A2, were found mutated to serine and isoleucine, respectively. The carboxamide groups of these strictly conserved asparagine side chains engage in strong hydrogen bonds with main-chain atoms from distant polypeptide regions (compare Figure 3C and 3I). It is therefore not surprising that replacements by serine (instead of Asn235) or isoleucine (at position 618) destabilize the domain structures, and the patients presented severe and moderate HA, respectively. Again, disease severity is comparable with other mutations affecting these and the equivalent residue, Asn1922 (Table 3). Of note, the recombinantly expressed mutant p.Asn618Ser FVIII accumulates intracellularly,45  and FVIII inhibitor development has been reported for patients carrying the Asn618Ser46  and Asn1922Asp mutations.47  Similar defects in protein secretion and inhibitor development might be expected for other mutations affecting Asn235, Asn618, or Asn1992, including the 2 novel mutations identified here.

Mutation p.His2082Asp represents the last example of a replacement that affects a polar residue. In the compact FVIIIa model, His2082 is essentially buried at the A3-C1 interface (Figure 1B); its imidazole ring engages in favorable interactions with residues from both domains (Figure 3K). Replacement by a negatively charged aspartate side chain would thus compromise the quaternary cofactor structure. On the other hand, formation of a salt bridge between Asp2082 and nearby Arg1869 might alleviate the consequences of this mutation, explaining the mild phenotype. We note that this residue has been alternatively hypothesized as part of a Mn2+-binding site in the quaternary arrangement of FVIIIa that locates domain C1 close to A1.4  Therefore, His2082 and neighboring residues represent a ground for a testable hypothesis about the prevalence of each conformation in circulating VWF-bound FVIII, its activated form, and FIXa-bound cofactor.

Missense mutations affecting buried Pro or Gly residues.

Six of the 20 novel missense mutations identified in the current work either introduce a proline instead of a conserved or conservatively replaced hydrophobic residue (p.Leu176Pro, p.Leu242Pro, and p.Gln2087Pro; Figure 2), or replace proline by arginine (at positions 477 and 550) or leucine (at 2153). The consequences of these mutations, however, depend on the precise location of the mutated residue. For instance, proline replacement for the strictly conserved Leu176 found in the middle of a major β-strand (Figures 2A,3B) would interfere with secondary structure formation. In addition, this change not only creates a cavity in the protein core, but also leads to clashes with residues from a neighboring strand (eg, Ser157). Thus, mutation p.Leu176Pro compromises cofactor folding at several levels; accordingly, it is associated with a severe bleeding phenotype, most likely related to absence of circulating FVIII. Severe HA results also from replacement of the strictly conserved Gln2087 by a proline (Figure 2B), as it disrupts an interaction network that clamps together sequentially distant polypeptide stretches of the C1 domain via strong H-bonds (Figure 3L). Interestingly, substitution of the equivalent Gln2246 by a polar arginine has been reported associated with moderate bleeding.48 

By contrast, the Leu242Pro replacement might be relatively well tolerated, as it does not affect a regular secondary structure element (Figure 2A). Moreover, a proline at this position retains favorable contacts with hydrophobic core residues while producing only minor clashes with the preceding Ser241. Finally, residues surrounding Leu242 are partially exposed and could be displaced to accommodate the mutant side chain (Figure 3D). These observations are in line with the moderate bleeding episodes described in this patient and with the mild disease form associated with the more conservative substitution, p.Leu625Val.49 

On the other hand, insertion of bulky, basic arginine side chains instead of strictly (Pro477) or well-conserved (Pro550) proline residues that are fully buried in the protein core (Figure 3G,H, respectively) would result in major disruption of the A2 domain fold, explaining the severe phenotypes of these patients. Similar phenotypes are associated with previously reported mutations of the Pro550-equivalent residue, Pro1854 (Table 3). We also note that these residues are found within repeated, well-conserved Gly-(Phe/Leu/Ile)-(Leu/Ile)-Gly-Pro motifs that appear to be critical for proper folding and trafficking of A domains.50 

Although apparently less deleterious, the strictly conserved Pro2153 (Figure 2B) is also buried in the protein core, and introduction of a bulkier, albeit aliphatic side chain (Leu) leads to major clashes with other core residues (Figure 3N). Gross fold destabilization would explain the severe bleeding associated with this mutation. Previous mutations of residue Pro2153 to Gln48,51  and Arg52,53  have been reported. It could have been expected that introduction of a polar side chain at this position has even more dramatic consequences than the Pro→Leu replacement identified here, and indeed p.Pro2153Arg is associated with severe HA.52,53  However, replacement by a glutamine results in mild51  or moderate HA,48  which is explained because the carboxamide group of Gln2153 could engage in H-bonding interactions with side chains of nearby polar residues (Figure 3N) compensating for steric clashes. The latter mutation has been previously associated with a reduced FVIII binding to von Willebrand factor.51  Because Pro2153 is essentially buried in the domain core, it is unlikely to engage in direct contacts with the carrier protein. On the other hand, we note that the neighboring residue, Arg2150 (Cα-Cα distance: 10 Å), is part of an important VWF-binding epitope.54  The observed impairment in VWF binding caused by replacement Pro2153Gln most probably results from enforced displacements of Arg2150 and surrounding residues. Conceivably, mutation p.Pro2153Leu also leads to impaired VWF binding and rapid cofactor clearance from blood, contributing to the severe phenotype.

Two mutations that affect glycine residues conserved in FVIII, p.Gly261Asp (Figure 2A) and p.Gly455Val, result in a mild bleeding phenotype. We note that small side chains are well tolerated at these positions given that topologically equivalent residues in FV and in other FVIII domains are Ala, Ser, or Thr. However, insertion of a charged aspartate at position 261 is unfavorable, mainly because of electrostatic repulsion from the nearby Glu265 (Figure 3E). Similarly, the replacement of Gly455 by Val would predict several, albeit minor, clashes with side chains of both nearby and sequentially distant residues (Figure 3F). Nevertheless, in both cases neighboring residues possess enough freedom to rotate away and alleviate these unfavorable interactions. In addition, introduction of Asp261 could be partially compensated by donating hydrogen bonds to the main-chain nitrogen atoms of Val201 and/or Phe202. The more severe phenotypes associated with 2 further mutations at position 455 (p.Gly455Glu, Waseem et al55  and p.Gly455Arg, Freson et al49 ) are explained by unfavorable van der Waals contacts of these bulkier, polar side chains in a mostly aromatic/hydrophobic environment. Moreover, the negatively charged side chain of Glu455 would be repelled by the Asp459 carboxylate (Figure 3F).

Conservative replacements of buried hydrophobic residues.

Replacement of the partially buried, strictly conserved Met2124 by a valine (Figure 2B) would minimally affect domain structure (Figure 3M), and the proband presented mild bleeding. Because of the conservative nature of mutations p.Ala1701Val, p.Phe1743Leu, and p.Ile2317Phe, they would also seem to be less detrimental. However, in these cases, the precise location of the mutated residue determines disease severity. Although introduction of the bulkier Val side chain at position 1701 leads to clashes with several residues (Figure 3J), the well-exposed Gln1778 side chain might rotate away to accommodate the extra methyl groups from Val1701. The replacement Ala1701Val, associated with mild HA, would have less dramatic implications than the p.Ala1701Asp mutation described in a severe case.15 

Similarly, mutation c.5286T>A that predicts replacement of the strictly conserved Phe1743 by the aliphatic leucine in a poorly conserved loop would seem to be well tolerated (Figure 3J). Indeed, mutation c.5284T>C leading to the same amino acid exchange has been previously reported in a patient suffering from mild bleeding.56  However, the fact that our proband presented moderate HA suggests that lack of loop-stabilizing interactions mediated by the Phe1743 side chain might disrupt the proper structure of the convoluted Phe1738-Tyr1762 loop. We hypothesize that this could in turn affect interactions with domain C1, or intermolecular contacts with FIXa (Figure 1B).

By contrast, mutation p.Ile2317Phe introduces a bulkier phenyl moiety instead of the strictly conserved aliphatic side chain at position 2317 (Figure 2B), and would lead to severe clashes with other conserved residues (Figure 3O). Aside from destabilizing important structural elements, loop rearrangements enforced by the inserted Phe2317 benzene ring could compromise interactions with VWF and/or membrane binding mediated by the C2 domain explaining the moderate bleeding phenotype associated with this mutation.

Type II mutations

Mutation p.Ala375Ser conservatively replaces the P3′ position within the activation cleavage site that separates domains A1 and A2. Previously, several mutations of the critical P1 residue Arg372 have been reported57-61  with phenotypes ranging from mild to severe. Replacement of the P1′ (p.Ser373Leu and p.Ser373Pro)62,63  and P2 residues (p.Ile371Thr)16  also compromises cleavage at this site and results in mild bleeding tendencies. Inspection of the thrombin structure,64,65  together with work conducted using synthetic peptide libraries66  and phage display,67  suggests a minor influence of positions on the nonprimed side of the P1-P1′ scissile peptide bond. In fact, serine appears to be slightly preferred over Ala at P3′ position, at least for thrombin inhibitors. However, these studies do not consider the key role played by interactions between thrombin exosites and acidic a1-a3 peptides during FVIII recognition and processing (eg, Glu331 to Asp363 for cleavage after Arg372). It is therefore conceivable that the mild bleeding phenotype associated with mutation p.Ala375Ser is due to a slightly decreased rate of cofactor activation.

Three additional mutations associated with mild or moderate bleeding phenotypes appear to either extend previously characterized or define novel protein-protein binding sites, based on their proximity to known interaction regions (Figure 1B). Mutation p.Pro64Arg replaces a proline conserved in FV and FVIII by a basic arginine side chain. By contrast, the topologically equivalent position is occupied by a glutamate or an aspartate in ceruloplasmin (Figure 2A), and the polar glutamate side chain is fully exposed in the crystal structure of the ferroxidase.9  Accordingly, inspection of the FVIIIa model revealed that an arginine side chain would be tolerated at this position. Because most residues within the long, irregular loop Thr55-Pro67 are well exposed, and considering their proximity to a1 (Figures 1B,5), it is conceivable that this area represents a binding site for substrate FX, which is partially masked by the mutant Arg64 side chain. Similar considerations apply to the p.Ala62Asp mutation, which has been reported in mild HA patients.16,17  Finally, and also in line with the hypothetical role of this region as a FX-interactive site, more dramatic loop rearrangements due to in-frame deletion of Pro66 or the Arg65/Pro66 pair lead to moderately severe and severe HA, respectively.68  Considering the predicted distance from the phospholipid membrane (Figure 1B), we speculate that this loop interacts with EGF2 and/or serine protease domains of substrate FX.

Figure 5

Location of solvent-exposed mutations on the FVIIIa surface. Solid surface representation of the 2 hypothesized quaternary arrangements of human FVIIIa, the “compact” (A) and “extended” models (B). Domains are labeled, and the distances from the phospholipid membrane are indicated (calculated as minimum distances between the C-terminal Cys residue in domain A1, Cys329, to a plane passing through Cα atoms of membrane-binding residues in C2, Met2199, Phe2200, and Leu2252). The side chains of 4 novel mutations affecting exposed residues, Pro64, Ala375, Gly494, and Asp2267, are represented as light magenta spheres. In addition, several residues previously reported to participate in VWF binding are highlighted as yellow spheres; other reported but not characterized mutations affecting exposed residues are in red. A curved arrow points to the probable displacement of C-terminal residues from the a1 linker to a more extended conformation after cleavage of the Arg372-Ser373 peptide bond. This would bring further residues implicated in FX binding (eg, the triplet of acidic residues Asp361/Asp362/Asp363; Nogami et al7 ) closer to the putative substrate binding site.

Figure 5

Location of solvent-exposed mutations on the FVIIIa surface. Solid surface representation of the 2 hypothesized quaternary arrangements of human FVIIIa, the “compact” (A) and “extended” models (B). Domains are labeled, and the distances from the phospholipid membrane are indicated (calculated as minimum distances between the C-terminal Cys residue in domain A1, Cys329, to a plane passing through Cα atoms of membrane-binding residues in C2, Met2199, Phe2200, and Leu2252). The side chains of 4 novel mutations affecting exposed residues, Pro64, Ala375, Gly494, and Asp2267, are represented as light magenta spheres. In addition, several residues previously reported to participate in VWF binding are highlighted as yellow spheres; other reported but not characterized mutations affecting exposed residues are in red. A curved arrow points to the probable displacement of C-terminal residues from the a1 linker to a more extended conformation after cleavage of the Arg372-Ser373 peptide bond. This would bring further residues implicated in FX binding (eg, the triplet of acidic residues Asp361/Asp362/Asp363; Nogami et al7 ) closer to the putative substrate binding site.

Close modal

Mutation p.Gly494Val maps to a particularly mobile, surface-exposed loop,9  which represents the major inhibitor epitope in FVIII A2 domain.69  Interestingly, both residues preceding and following Gly494 have been implicated in FX binding, in particular the basic cluster Arg489/Arg490/Lys493.4,70  It is conceivable that a bulkier side chain at position 494 would impair these FVIIIa-FX interactions, thus compromising substrate recognition. Moderate bleeding has also been reported for mutant p.Gly494Ser,68  also in line with the proposed involvement of this loop in FX activation. We note that a discrepancy between antigen and FVIII activity levels for the latter mutant (23% and 4%, respectively) suggests its involvement in intermolecular interactions. As alternative to FX binding, and because the 484 to 509 loop represents a major binding site for low-density lipoprotein receptor–related protein (LRP),4,71  our mutation p.Gly494Val could reduce the half-life of circulating FVIII by enhancing binding to its hepatic clearance receptor.

Finally, mutation p.Asp2267Gly eliminates a partially exposed aspartate side chain within a loop that is poorly conserved between FV and FVIII (Figure 2B). One of the carboxylate oxygens from Asp2267 accepts hydrogen bonds from the main-chain nitrogen atoms of 2 consecutive loop residues (Figure 4). The topologically equivalent position, however, is occupied by Gln/Arg in FV (Figure 2B), and in spite of this fact the loop conformation is almost identical in all the experimentally solved structures of natural or recombinant C2 domains, both from FV2,72  and FVIII8,41  (Figure 4). Therefore, Asp2267 appears to be dispensable for C2 structural stability. Inspection of the model suggests that most residues within the convoluted, bowtie-shaped Gln2266-Lys2281 loop are well exposed in FVIIIa, and are thus available for intermolecular interactions (Figure 2B). In this regard, we also noticed that this region is the most variable between FV and FVIII discoidin-like domains (Figure 4), pointing to a cofactor-specific role. In the light of its neighborhood to other residues previously associated with VWF binding11,73  (Figure 5), this area might represent an extension of the well-characterized VWF-binding site(s). Alternatively, and given the relatively close distance to the phospholipid membrane (Figures 1B and 5), residues from this loop and in particular Asp2267 might contact the Gla or EGF1 domains from substrate FX.

In conclusion, we characterized 31 novel mutations in the F8 gene including a further evaluation and interpretation of 20 novel missense mutations combining bioinformatics tools and current knowledge of FV/FVIII structure/function relationships. Our thorough analysis of the novel mutations provides further insights into the causes of hemophilia A, contributes to a better understanding of the functional consequences of F8 mutations, and suggests novel FX-interaction areas on the cofactor surface. Future investigations using recombinant proteins should validate these results, and refine current models for FVIIIa and FVIIIapi•FIXa (Xase) structures.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

We thank all patients and their relatives for participating in this study. We are indebted to A. Alonso, C. Altisent, M. T. Calvo, L. Eciolaza, J. Fontcuberta, R. González Boullosa, F. Lucía, M. A. Lopez Aristegui, M. F. López Fernández, J. Martorell, J. Monteagudo, M. Moreno, R. Pérez Garrido, M. Quintana, J. Rosell, C. Sedano, J. Tusell, F. Velasco, and A. Villar for clinical information about these patients.

This work was supported by Fundació Catalana d′Hemofilia and grant SAF2004-00543 from Spanish Ministerio de Educación y Ciencia.

National Institutes of Health

Contribution: A.V., P.F.-P., and E.F.T. designed the research, analyzed data, and wrote the paper; P.F.-P. and M.A.C.-R. performed modeling and produced figures; M. Baena, M.C., and M.D. performed experiments to identify mutations; M. Baiget gave intellectual support and discussion on the paper; E.F.T. was primarily responsible for this work.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Eduardo F. Tizzano, Department of Genetics, Hospital de la Santa Creu i Sant Pau, Sant Antoni Ma. Claret 167, 08025 Barcelona, Spain; e-mail: [email protected].

1
White
 
GC
Rosendaal
 
F
Aledort
 
LM
et al. 
Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis [letter].
Thromb Haemost
2001
, vol. 
85
 pg. 
560
 
2
Adams
 
TE
Hockin
 
MF
Mann
 
KG
Everse
 
SJ
The crystal structure of activated protein C-inactivated bovine factor Va: Implications for cofactor function.
Proc Natl Acad Sci U S A
2004
, vol. 
101
 (pg. 
8918
-
8923
)
3
Shen
 
BW
Spiegel
 
PC
Chang
 
C-H
et al. 
The tertiary structure and domain organization of coagulation factor VIII.
Blood
2008
, vol. 
111
 (pg. 
1240
-
1247
)
4
Fay
 
PJ
Jenkins
 
PV
Mutating factor VIII: lessons from structure to function.
Blood Rev
2005
, vol. 
19
 (pg. 
15
-
27
)
5
Graw
 
J
Brackmann
 
HH
Oldenburg
 
J
Schneppenheim
 
R
Spannagl
 
M
Schwaab
 
R
Haemophilia A: from mutation analysis to new therapies.
Nat Rev Genet
2005
, vol. 
6
 (pg. 
488
-
501
)
6
Lapan
 
KA
Fay
 
PJ
Localization of a Factor X interactive site in the A1 subunit of Factor VIIIa.
J Biol Chem
1997
, vol. 
272
 (pg. 
2082
-
2088
)
7
Nogami
 
K
Freas
 
J
Manithody
 
C
Wakabayashi
 
H
Rezaie
 
AR
Fay
 
PJ
Mechanisms of interactions of Factor X and Factor Xa with the acidic region in the Factor VIII A1 domain.
J Biol Chem
2004
, vol. 
279
 (pg. 
33104
-
33113
)
8
Pratt
 
KP
Shen
 
BW
Takeshima
 
K
Davie
 
EW
Fujikawa
 
K
Stoddard
 
BL
Structure of the C2 domain of human factor VIII at 1.5 A resolution.
Nature
1999
, vol. 
402
 (pg. 
439
-
442
)
9
Zaitseva
 
I
Zaitsev
 
V
Card
 
G
et al. 
The X-ray structure of human serum ceruloplasmin at 3.1 Angstrom-Nature of the copper centres.
J Biol Inorg Chem
1996
, vol. 
1
 (pg. 
15
-
23
)
10
Pemberton
 
S
Lindley
 
P
Zaitsev
 
V
Card
 
G
Tuddenham
 
EGD
Kemball-Cook
 
G
A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin.
Blood
1997
, vol. 
89
 (pg. 
2413
-
2421
)
11
Liu
 
M-L
Shen
 
BW
Nakaya
 
S
et al. 
Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure.
Blood
2000
, vol. 
96
 (pg. 
979
-
987
)
12
Stoilova-McPhie
 
S
Villoutreix
 
BO
Mertens
 
K
Kemball-Cook
 
G
Holzenburg
 
A
3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography.
Blood
2002
, vol. 
99
 (pg. 
1215
-
1223
)
13
Autin
 
L
Miteva
 
MA
Lee
 
WH
Mertens
 
K
Radtke
 
KP
Villoutreix
 
BO
Molecular models of the procoagulant Factor VIIIa-Factor IXa complex.
J Thromb Haemost
2005
, vol. 
3
 (pg. 
2044
-
2056
)
14
HAMSTeRS Database.
accessed November 18, 2007 
15
David
 
D
Ventura
 
C
Moreira
 
I
et al. 
The spectrum of mutations and molecular pathogenesis of hemophilia A in 181 Portuguese patients.
Haemotologica
2006
, vol. 
91
 (pg. 
840
-
843
)
16
Guillet
 
B
Lambert
 
T
d'Oiron
 
R
et al. 
Detection of 95 novel mutations in coagulation factor VIII gene F8 responsible for hemophilia A: results from a single institution.
Hum Mutat
2006
, vol. 
27
 (pg. 
676
-
685
)
17
Repesse
 
Y
Slaoui
 
M
Ferrandiz
 
D
et al. 
Factor VIII (FVIII) gene mutations in 120 patients with hemophilia A: detection of 26 novel mutations and correlation with FVIII inhibitor development.
J Thromb Haemost
2007
, vol. 
5
 (pg. 
1469
-
1476
)
18
Rossetti
 
LC
Radic
 
CP
Candela
 
M
et al. 
Sixteen novel hemophilia A causative mutations in the first Argentinian series of severe molecular defects.
Haematologica
2007
, vol. 
92
 (pg. 
842
-
845
)
19
David
 
D
Moreira
 
I
Lalloz
 
MRA
et al. 
Analysis of the essential sequences of the factor VIII gene in twelve haemophilia A patients by single-stranded conformation polymorphism.
Blood Coagul Fibrinolysis
1994
, vol. 
5
 (pg. 
257
-
264
)
20
Boekhorst
 
J
Verbruggen
 
B
Lavergne
 
JM
et al. 
Thirteen novel mutations in the factor VIII gene in the Nijmegen haemophilia A patient population.
Brit J Haematol
2005
, vol. 
131
 (pg. 
109
-
117
)
21
National Institutes of Health.
GenBank.
accessed August 17, 2007 
22
Den Dunnen
 
J
Antonarakis
 
SE
Nomenclature for the description of human sequence variations.
Hum Genet
2001
, vol. 
109
 (pg. 
121
-
124
)
23
Schechter
 
I
Berger
 
A
On the size of the active site in proteases.
Biochem Biophys Res Com
1967
, vol. 
27
 (pg. 
157
-
162
)
24
Parthiban
 
V
Gromiha
 
MM
Schomburg
 
D
CUPSAT: prediction of protein stability upon point mutations.
Nucl Acids Res
2006
, vol. 
34
 (pg. 
W239
-
W242
)
25
SWISS-MODEL Database.
accessed August 17, 2007 
26
Schwede
 
T
Kopp
 
J
Guex
 
N
Peitsch
 
MC
SWISS-MODEL: an automated protein homology-modeling server.
Nucl Acids Res
2003
, vol. 
31
 (pg. 
3381
-
3385
)
27
Protein Database
accessed August 17, 2007 
28
Kamata
 
K
Kawamoto
 
H
Honma
 
T
Iwama
 
T
Kim
 
S-H
Structural basis for chemical inhibition of human blood coagulation factor Xa.
Proc Natl Acad Sci U S A
1998
, vol. 
95
 (pg. 
6630
-
6635
)
29
Mizuno
 
H
Fujimoto
 
Z
Atoda
 
H
Morita
 
T
Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X.
Proc Natl Acad Sci U S A
2001
, vol. 
98
 (pg. 
7230
-
7234
)
30
Sunnerhagen
 
M
Olah
 
GA
Stenflo
 
J
Forsen
 
S
Drakenberg
 
T
Trewhella
 
J
The relative orientation of Gla and EGF domains in coagulation factor X is altered by Ca2+ binding to the first EGF domain: a combined NMR-small angle X-ray scattering study.
Biochemistry
1996
, vol. 
35
 (pg. 
11547
-
11559
)
31
Wang
 
D
Bode
 
W
Huber
 
R
Bovine chymotrypsinogen A X-ray crystal structure analysis and refinement of a new crystal form at 1.8 A resolution.
J Mol Biol
1985
, vol. 
185
 (pg. 
595
-
624
)
32
Brandstetter
 
H
Bauer
 
M
Huber
 
R
Lollar
 
P
Bode
 
W
X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B.
Proc Natl Acad Sci U S A
1995
, vol. 
92
 (pg. 
9796
-
9800
)
33
Shikamoto
 
Y
Morita
 
T
Fujimoto
 
Z
Mizuno
 
H
Crystal structure of Mg2+- and Ca2+-bound Gla domain of Factor IX complexed with binding protein.
J Biol Chem
2003
, vol. 
278
 (pg. 
24090
-
24094
)
34
Huang
 
M
Furie
 
BC
Furie
 
B
Crystal structure of the calcium-stabilized human Factor IX Gla domain bound to a conformation-specific anti-factor IX antibody.
J Biol Chem
2004
, vol. 
279
 (pg. 
14338
-
14346
)
35
Venkateswarlu
 
D
Perera
 
L
Darden
 
T
Pedersen
 
LG
Structure and dynamics of zymogen human blood coagulation factor X.
Biophys J
2002
, vol. 
82
 (pg. 
1190
-
1206
)
36
Ansong
 
C
Fay
 
PJ
Factor VIII A3 domain residues 1954-1961 represent an A1 domain-interactive site.
Biochemistry
2005
, vol. 
44
 (pg. 
8850
-
8857
)
37
Kim
 
SW
Quinn-Allen
 
MA
Camp
 
JT
et al. 
Identification of functionally important amino acid residues within the C2-domain of human factor V using alanine-scanning mutagenesis.
Biochemistry
2000
, vol. 
39
 (pg. 
1951
-
1958
)
38
Saleh
 
M
Peng
 
W
Quinn-Allen
 
MA
et al. 
The factor V C1 domain is involved in membrane binding: identification of functionally important amino acid residues within the C1 domain of factor V using alanine scanning mutagenesis.
Thromb Haemost
2004
, vol. 
91
 (pg. 
16
-
27
)
39
Nicolaes
 
GA
Villoutreix
 
BO
Dahlback
 
B
Mutations in a potential phospholipid binding loop in the C2 domain of factor V affecting the assembly of the prothrombinase complex.
Blood Coagul Fibrinolysis
2000
, vol. 
11
 (pg. 
89
-
100
)
40
Barrow
 
RT
Healey
 
JF
Jacquemin
 
MG
Saint-Remy
 
JMR
Lollar
 
P
Antigenicity of putative phospholipid membrane-binding residues in factor VIII.
Blood
2001
, vol. 
97
 (pg. 
169
-
174
)
41
Spiegel
 
PC
Jacquemin
 
M
Saint-Remy
 
J-MR
Stoddard
 
BL
Pratt
 
KP
Structure of a factor VIII C2 domain-immunoglobulin G4{kappa} Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII.
Blood
2001
, vol. 
98
 (pg. 
13
-
19
)
42
Fuentes-Prior
 
P
Fujikawa
 
K
Pratt
 
KP
New insights into binding interfaces of coagulation factors V and VIII and their homologues lessons from high resolution crystal structures.
Curr Protein Pept Sci
2002
, vol. 
3
 (pg. 
313
-
339
)
43
David
 
D
Santos
 
IMA
Johnson
 
K
Tuddenham
 
EGD
McVey
 
JH
Analysis of the consequences of premature termination codons within factor VIII coding sequences.
J Thromb Haemost
2003
, vol. 
1
 (pg. 
139
-
146
)
44
Bogdanova
 
N
Markoff
 
A
Eisert
 
R
et al. 
Spectrum of molecular defects and mutation detection rate in patients with mild and moderate hemophilia A.
Hum Mutat
2007
, vol. 
28
 (pg. 
54
-
60
)
45
Roelse
 
JC
de Laaf
 
RT
Timmermans
 
SM
Peters
 
M
van Mourik
 
JA
Voorberg
 
J
Intracellular accumulation of factor VIII induced by missense mutations Arg593→Cys and Asn618→Ser explains cross-reacting material-reduced haemophilia A.
Br J Haematol
2000
, vol. 
108
 (pg. 
241
-
246
)
46
Vlot
 
AJ
Wittebol
 
S
Strengers
 
PFW
et al. 
Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618→Ser mutation responsive to immune tolerance induction and cyclophosphamide.
Br J Haematol
2002
, vol. 
117
 (pg. 
136
-
140
)
47
Traystman
 
MD
Higuchi
 
M
Kasper
 
CK
Antonarakis
 
SE
Kazazian
 
HH
Use of denaturing gradient gel electrophoresis to detect point mutations in the factor VIII gene.
Genomics
1990
, vol. 
6
 (pg. 
293
-
301
)
48
Schwaab
 
R
Oldenburg
 
J
Schwaab
 
U
et al. 
Characterization of mutations within the factor VIII gene of 73 unrelated mild and moderate haemophiliacs.
Br J Haematol
1995
, vol. 
91
 (pg. 
458
-
464
)
49
Freson
 
K
Peerlinck
 
K
Aguirre
 
T
et al. 
Fluorescent chemical cleavage of mismatches for efficient screening of the factor VIII gene.
Hum Mutat
1998
, vol. 
11
 (pg. 
470
-
479
)
50
Kono
 
S
Miyajima
 
H
Molecular and pathological basis of aceruloplasminemia.
Biol Res
2006
, vol. 
39
 (pg. 
15
-
23
)
51
Jacquemin
 
M
Lavend'homme
 
R
Benhida
 
A
et al. 
A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.
Blood
2000
, vol. 
96
 (pg. 
958
-
965
)
52
Ivaskevicius
 
V
Jurgutis
 
R
Rost
 
S
et al. 
Lithuanian haemophilia A and B registry comprising phenotypic and genotypic data.
Br J Haematol
2001
, vol. 
112
 (pg. 
1062
-
1070
)
53
Leuer
 
M
Oldenburg
 
J
Lavergne
 
J-M
et al. 
Somatic mosaicism in hemophilia A: a fairly common event.
Am J Hum Genet
2001
, vol. 
69
 (pg. 
75
-
87
)
54
Jacquemin
 
M
Benhida
 
A
Peerlinck
 
K
et al. 
A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.
Blood
2000
, vol. 
95
 (pg. 
156
-
163
)
55
Waseem
 
NH
Bagnall
 
R
Green
 
PM
Giannelli
 
F
Start of UK confidential haemophilia A database: analysis of 142 patients by solid phase fluorescent chemical cleavage of mismatch.
Thromb Haemost
1999
, vol. 
81
 (pg. 
900
-
905
)
56
Ahmed
 
RP
Ivaskevicius
 
V
Kannan
 
M
Seifried
 
E
Oldenburg
 
J
Saxena
 
R
Identification of 32 novel mutations in the factor VIII gene in Indian patients with hemophilia A.
Haematologica
2005
, vol. 
90
 (pg. 
283
-
284
)
57
Bicocchi
 
MP
Migeon
 
BR
Pasino
 
M
et al. 
Familial nonrandom inactivation linked to the X inactivation centre in heterozygotes manifesting haemophilia A.
Eur J Hum Genet
2005
, vol. 
13
 (pg. 
635
-
640
)
58
Arai
 
M
Inaba
 
H
Higuchi
 
M
et al. 
Direct characterization of Factor VIII in plasma: Detection of a mutation altering a thrombin cleavage site (arginine-372→histidine).
Proc Natl Acad Sci U S A
1989
, vol. 
86
 (pg. 
4277
-
4281
)
59
Pattinson
 
JK
Millar
 
DS
McVey
 
JH
et al. 
The molecular genetic analysis of hemophilia A: a directed search strategy for the detection of point mutations in the human factor VIII gene.
Blood
1990
, vol. 
76
 (pg. 
2242
-
2248
)
60
Shima
 
M
Ware
 
J
Yoshioka
 
A
Fukui
 
H
Fulcher
 
CA
An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule.
Blood
1989
, vol. 
74
 (pg. 
1612
-
1617
)
61
Lavergne
 
JM
Bahnak
 
BR
Vidaud
 
M
Laurian
 
Y
Meyer
 
D
A directed search for mutations in hemophilia A using restriction enzyme analysis and denaturing gradient gel electrophoresis: a study of seven exons in the factor VIII gene of 170 cases.
Nouv Rev Fr Hematol
1992
, vol. 
34
 (pg. 
85
-
91
)
62
Acquila
 
M
Pasino
 
M
Lanza
 
T
Bottini
 
F
Molinari
 
AC
Bicocchi
 
MP
Two novel mutations at 373 codon of FVIII gene detected by DGGE.
Thromb Haemost
1993
, vol. 
69
 (pg. 
392
-
393
)
63
Johnson
 
DJ
Pemberton
 
S
Acquila
 
M
Mori
 
PG
Tuddenham
 
EG
O'Brien
 
DP
Factor VIII S373L: mutation at P1′ site confers thrombin cleavage resistance, causing mild haemophilia A.
Thromb Haemost
1994
, vol. 
71
 (pg. 
428
-
433
)
64
Bode
 
W
Mayr
 
I
Baumann
 
U
Huber
 
R
Stone
 
SR
Hofsteenge
 
J
The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment.
EMBO J
1989
, vol. 
8
 (pg. 
3467
-
3475
)
65
Bode
 
W
Turk
 
D
Karshikov
 
A
The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships.
Protein Sci
1992
, vol. 
1
 (pg. 
426
-
471
)
66
Petrassi
 
HM
Williams
 
JA
Li
 
J
et al. 
A strategy to profile prime and non-prime proteolytic substrate specificity.
Bioorg Med Chem Lett
2005
, vol. 
15
 (pg. 
3162
-
3166
)
67
Su
 
Z
Vinogradova
 
A
Koutychenko
 
A
Tolkatchev
 
D
Ni
 
F
Rational design and selection of bivalent peptide ligands of thrombin incorporating P4-P1 tetrapeptide sequences: from good substrates to potent inhibitors.
Protein Eng Des Sel
2004
, vol. 
17
 (pg. 
647
-
657
)
68
Liu
 
M-L
Nakaya
 
S
Thompson
 
AR
Non-inversion Factor VIII mutations in 80 hemophilia A families including 24 with alloimmune responses.
Thromb Haemost
2002
, vol. 
87
 (pg. 
273
-
276
)
69
Lubin
 
IM
Healey
 
JF
Barrow
 
RT
Scandella
 
D
Lollar
 
P
Analysis of the human Factor VIII A2 inhibitor epitope by alanine scanning mutagenesis.
J Biol Chem
1997
, vol. 
272
 (pg. 
30191
-
30195
)
70
Jenkins
 
PV
Dill
 
JL
Zhou
 
Q
Fay
 
PJ
Clustered basic residues within segment 484-510 of the factor VIIIa A2 subunit contribute to the catalytic efficiency for factor Xa generation.
J Thromb Haemost
2004
, vol. 
2
 (pg. 
452
-
458
)
71
Sarafanov
 
AG
Makogonenko
 
EM
Pechik
 
IV
et al. 
Identification of coagulation factor VIII A2 domain residues forming the binding epitope for Low-Density Lipoprotein Receptor-Related Protein.
Biochemistry
2006
, vol. 
45
 (pg. 
1829
-
1840
)
72
Macedo-Ribeiro
 
S
Bode
 
W
Huber
 
R
et al. 
Crystal structures of the membrane-binding C2 domain of human coagulation factor V.
Nature
1999
, vol. 
402
 (pg. 
434
-
439
)
73
Spiegel
 
PC
Murphy
 
P
Stoddard
 
BL
Surface-exposed hemophilic mutations across the Factor VIII C2 domain have variable effects on stability and binding activities.
J Biol Chem
2004
, vol. 
279
 (pg. 
53691
-
53698
)
74
Cutler
 
JA
Mitchell
 
MJ
Smith
 
MP
Savidge
 
GF
The identification and classification of 41 novel mutations in the factor VIII gene (F8C).
Hum Mutat
2002
, vol. 
19
 (pg. 
274
-
278
)
75
Akkarapatumwong
 
V
Oranwiroon
 
S
Pung-amritt
 
P
et al. 
Mutations of the factor VIII gene in Thai hemophilia A patients.
Hum Mutat
2000
, vol. 
15
 (pg. 
117
-
118
)
76
Higuchi
 
M
Kazazian
 
HH
Kasch
 
L
et al. 
Molecular characterization of severe hemophilia A suggests that about half the mutations are not within the coding regions and splice junctions of the Factor VIII gene.
Proc Natl Acad Sci U S A
1991
, vol. 
88
 (pg. 
7405
-
7409
)
77
McGinniss
 
MJ
Kazazian
 
HH
Hoyer
 
LW
Bi
 
L
Inaba
 
H
Antonarakis
 
SE
Spectrum of mutations in CRM-positive and CRM-reduced hemophilia A.
Genomics
1993
, vol. 
15
 (pg. 
392
-
398
)
78
Bogdanova
 
N
Markoff
 
A
Pollmann
 
H
et al. 
Spectrum of molecular defects and mutation detection rate in patients with severe hemophilia A.
Hum Mutat
2005
, vol. 
26
 (pg. 
249
-
254
)
79
Becker
 
J
Schwaab
 
R
Moeller-Taube
 
A
et al. 
Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: family studies indicate a mutation type-dependent sex ratio of mutation frequencies.
Am J Hum Genet
1996
, vol. 
58
 (pg. 
657
-
670
)
80
Casana
 
P
Haya
 
S
Cid
 
AR
et al. 
Abstract PO11.
Haemophilia
2004
, vol. 
10
 (pg. 
73
-
78
)
81
Bicocchi
 
MP
Pasino
 
M
Lanza
 
T
et al. 
Analysis of 18 novel mutations in the factor VIII gene.
Br J Haematol
2003
, vol. 
122
 (pg. 
810
-
817
)
82
Arruda
 
VR
Pieneman
 
WC
Reitsma
 
PH
et al. 
Eleven novel mutations in the factor VIII gene from Brazilian hemophilia A patients.
Blood
1995
, vol. 
86
 (pg. 
3015
-
3020
)
83
Diamond
 
C
Kogan
 
S
Levinson
 
B
Gitschier
 
J
Amino acid substitutions in conserved domains of factor VIII and related proteins: study of patients with mild and moderately severe hemophilia A.
Hum Mutat
1992
, vol. 
1
 (pg. 
248
-
257
)
84
Sukarova-Stefanovska
 
E
Zisovski
 
N
Muratovska
 
O
Kostova
 
S
Efremov
 
GD
Three novel point mutations causing haemophilia A.
Haemophilia
2002
, vol. 
8
 (pg. 
715
-
718
)
85
Vinciguerra
 
C
Zawadzki
 
C
Dargaud
 
Y
et al. 
Characterisation of 96 mutations in 128 unrelated severe haemophilia A patients from France: description of 62 novel mutations.
Thromb Haemost
2006
, vol. 
95
 (pg. 
593
-
599
)
86
Bogdanova
 
N
Lemcke
 
B
Markoff
 
A
et al. 
Seven novel and four recurrent point mutations in the factor VIII (F8C) gene.
Hum Mutat
2001
, vol. 
18
 pg. 
546
  
[letter]
Sign in via your Institution